Hemab Therapeutics (COAG) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.34 billion vs $1.11 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | VOR |
|---|---|---|
| Share price | $28.70 | $18.78 |
| Market cap | $1.34B | $1.11B |
| 1-day change | +1.16% | +2.57% |
| 5-year return | — | -93.93% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-4.33 | $180.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $34.63 |
| 52-week low | $23.00 | $6.50 |
| Distance from 52-week high | -48.21% | -45.77% |
| Average volume | 453.50K | 1.02M |
| Shares outstanding | 46.71M | 59.16M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
COAG vs VOR FAQ
Which is bigger, Hemab Therapeutics or Vor Biopharma?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.34B compared with $1.11B for Vor Biopharma (VOR).
Are Hemab Therapeutics and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.